OCUMENSION-B (01477) has announced that the first patient has been enrolled in the Phase III clinical trial for OT-211 (AR-15512) conducted in China. OT-211 (AR-15512) is a 0.003% ophthalmic solution formulation and is the first TRPM8 agonist approved by the U.S. Food and Drug Administration (FDA) for treating the signs and symptoms of dry eye disease (DED). The successful enrollment of the first patient marks a significant milestone in the clinical development of OT-211 in China and demonstrates the company's commitment to advancing innovative therapies for DED patients. Alcon Inc., a global leader in eye care with complementary businesses in surgical and vision care, developed the 0.003% ophthalmic solution formulation of AR-15512 and completed one Phase IIb and three Phase III clinical trials. OT-211 (AR-15512) received FDA approval for treating DED signs and symptoms on May 28, 2025. Following a strategic collaboration with the Alcon Group in October 2024, OCUMENSION-B secured an exclusive license to develop, manufacture, have manufactured, import, export, and sell OT-211 (AR-15512) in mainland China.